

Special Issue

Epigenetic Regulation of Solid Tumors

Message from the Guest Editors

Tumors are aggressive diseases with a high mortality rate and a costly treatment process. As the majority of cancer cases are firstly diagnosed at an advanced stage and with metastasis, the current management of cancer faces serious challenges, despite the development of advanced therapeutics. Therefore, employing cutting-edge bio-informatics, sequence technology and molecular biology to develop novel biomarkers for the accurate screening, detection, diagnosis, and prognosis prediction of cancer is essential in order to enhance patients' survival rate.

Increasing evidence indicates that epigenetic modifications, including DNA/RNA methylation, histone modifications, and non-coding RNAs (ncRNAs), have gained substantial attention in recent years, as it is now well established that these aberrations are significant biomarkers for tumor diagnosis, prognosis, and treatment response.

For this Special Issue, we invite basic and clinical oncologists to submit their contributions, including reviews, new methods, and original research, related to the role of epigenetics in tumor diagnosis and prognosis.

Guest Editors

Dr. Donghong Zhang

Raybiotech, Atlanta, GA 30092, USA

Dr. Yuning Hou

Cancer Animal Models Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA

Dr. Xina Xie

The First Affiliated Hospital of Shenzhen University, Shenzhen 518000, China

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/182135

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).